243 related articles for article (PubMed ID: 33019490)
1. Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report.
Zhang X; Liang Y; Li X; Wang W; Tong J; Xu Y
Medicine (Baltimore); 2020 Oct; 99(40):e22642. PubMed ID: 33019490
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.
Ataca Atilla P; Yalçıner M; Atilla E; İdilman R; Beksaç M
Turk J Haematol; 2019 Nov; 36(4):266-273. PubMed ID: 31368290
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant.
Li J; Huang B; Li Y; Zheng D; Zhou Z; Liu J
Leuk Lymphoma; 2015 Jun; 56(6):1710-7. PubMed ID: 25098429
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lau EHY; Cheung KS; Lie AKW; Lai CL; Kwong YL; Yuen MF
Hepatology; 2017 May; 65(5):1451-1461. PubMed ID: 28027590
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area.
Wu Y; Chen Y; Zhu P; Ye B; Lu Y; Shi J; Tan Y; Zhao Y; Yu J; Lai X; Lan J; Si T; Ni L; Huang H; Luo Y
Ann Hematol; 2022 Mar; 101(3):631-641. PubMed ID: 34981143
[TBL] [Abstract][Full Text] [Related]
7. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
[TBL] [Abstract][Full Text] [Related]
8. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
[TBL] [Abstract][Full Text] [Related]
9. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports.
Yoshida T; Kusumoto S; Inagaki A; Mori F; Ito A; Ri M; Ishida T; Komatsu H; Iida S; Sugauchi F; Tanaka Y; Mizokami M; Ueda R
Int J Hematol; 2010 Jun; 91(5):844-9. PubMed ID: 20473594
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
13. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
14. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature.
Türker K; Albayrak M; Öksüzoğlu B; Balc E; Oğan MC; Iskender G; Altuntaş F
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):39-45. PubMed ID: 25076063
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study.
Lu J; Chen WM; Geng CY; Durie BG; Huang XJ
Chin Med J (Engl); 2016 Feb; 129(3):274-8. PubMed ID: 26831227
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.
Tanaka H; Sakuma I; Hashimoto S; Takeda Y; Sakai S; Takagi T; Shimura T; Nakaseko C
J Clin Exp Hematop; 2012; 52(1):67-9. PubMed ID: 22706534
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation.
Li J; Liu J; Huang B; Zheng D; Chen M; Zhou Z; Xu D; Zou W
Tumour Biol; 2013 Jun; 34(3):1723-8. PubMed ID: 23436046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
